Click for best price
Broluzumab Biosimilars Market Size, Share 2022
Market Analysis and Insights: Global Broluzumab Biosimilars Market
The global Broluzumab Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Broluzumab Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Broluzumab Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Broluzumab Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Broluzumab Biosimilars market.
Global Broluzumab Biosimilars Scope and Market Size
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Segment by Application
- ARMD
- Kaposi Sarcoma
- Glioblastoma
By Region
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
By Company
- Novartis
- Genentech
- Roche
- Pfizer
- Sartorius
- Eli Lilly
- Bayer
- Amgen
- PlantForm
- PharmaPraxis
- Samsung Bioepis
- Centus
- Cadila Pharmaceuticals
- Dr Reddy's
- Aurobindo Pharma
- Biocad
- MAbxience
- Hetero
- Biocon
- Kirin Biologics
- Mylan
- BeiGene
- Innovent
- Qilu Pharmaceutical
- Hengrui Pharmaceuticals
- Hisun Pharmaceutical
- TOT BIOPHARM
- Luye Pharmaceutical
- Henlius
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Broluzumab Biosimilars product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Broluzumab Biosimilars, with price, sales, revenue, and global market share of Broluzumab Biosimilars from 2019 to 2022.
Chapter 3, the Broluzumab Biosimilars competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Broluzumab Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Broluzumab Biosimilars market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Broluzumab Biosimilars.
Chapter 13, 14, and 15, to describe Broluzumab Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Broluzumab Biosimilars Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global Broluzumab Biosimilars Market Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
119 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Broluzumab Biosimilars Market Overview
1.1 Product Overview and Scope of Broluzumab Biosimilars
1.2 Broluzumab Biosimilars Segment by Type
1.2.1 Global Broluzumab Biosimilars Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Beovu
1.2.3 Vsiqq
1.2.4 Others
1.3 Broluzumab Biosimilars Segment by Application
1.3.1 Global Broluzumab Biosimilars Sales Comparison by Application: (2022-2028)
1.3.2 ARMD
1.3.3 Kaposi Sarcoma
1.3.4 Glioblastoma
1.4 Global Broluzumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Broluzumab Biosimilars Revenue 2017-2028
1.4.2 Global Broluzumab Biosimilars Sales 2017-2028
1.4.3 Broluzumab Biosimilars Market Size by Region: 2017 Versus 2021 Versus 2028
2 Broluzumab Biosimilars Market Competition by Manufacturers
2.1 Global Broluzumab Biosimilars Sales Market Share by Manufacturers (2017-2022)
2.2 Global Broluzumab Biosimilars Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Broluzumab Biosimilars Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Broluzumab Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Broluzumab Biosimilars Market Competitive Situation and Trends
2.5.1 Broluzumab Biosimilars Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Broluzumab Biosimilars Players Market Share by Revenue
2.5.3 Global Broluzumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Broluzumab Biosimilars Retrospective Market Scenario by Region
3.1 Global Broluzumab Biosimilars Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Broluzumab Biosimilars Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Broluzumab Biosimilars Market Facts & Figures by Country
3.3.1 North America Broluzumab Biosimilars Sales by Country
3.3.2 North America Broluzumab Biosimilars Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Broluzumab Biosimilars Market Facts & Figures by Country
3.4.1 Europe Broluzumab Biosimilars Sales by Country
3.4.2 Europe Broluzumab Biosimilars Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Broluzumab Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Broluzumab Biosimilars Sales by Region
3.5.2 Asia Pacific Broluzumab Biosimilars Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Broluzumab Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Broluzumab Biosimilars Sales by Country
3.6.2 Latin America Broluzumab Biosimilars Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Broluzumab Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Broluzumab Biosimilars Sales by Country
3.7.2 Middle East and Africa Broluzumab Biosimilars Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Broluzumab Biosimilars Historic Market Analysis by Type
4.1 Global Broluzumab Biosimilars Sales Market Share by Type (2017-2022)
4.2 Global Broluzumab Biosimilars Revenue Market Share by Type (2017-2022)
4.3 Global Broluzumab Biosimilars Price by Type (2017-2022)
5 Global Broluzumab Biosimilars Historic Market Analysis by Application
5.1 Global Broluzumab Biosimilars Sales Market Share by Application (2017-2022)
5.2 Global Broluzumab Biosimilars Revenue Market Share by Application (2017-2022)
5.3 Global Broluzumab Biosimilars Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Novartis Broluzumab Biosimilars Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Genentech
6.2.1 Genentech Corporation Information
6.2.2 Genentech Description and Business Overview
6.2.3 Genentech Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Genentech Broluzumab Biosimilars Product Portfolio
6.2.5 Genentech Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Roche Broluzumab Biosimilars Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Broluzumab Biosimilars Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Sartorius
6.5.1 Sartorius Corporation Information
6.5.2 Sartorius Description and Business Overview
6.5.3 Sartorius Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Sartorius Broluzumab Biosimilars Product Portfolio
6.5.5 Sartorius Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Eli Lilly Broluzumab Biosimilars Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bayer Broluzumab Biosimilars Product Portfolio
6.7.5 Bayer Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Amgen Broluzumab Biosimilars Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 PlantForm
6.9.1 PlantForm Corporation Information
6.9.2 PlantForm Description and Business Overview
6.9.3 PlantForm Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.9.4 PlantForm Broluzumab Biosimilars Product Portfolio
6.9.5 PlantForm Recent Developments/Updates
6.10 PharmaPraxis
6.10.1 PharmaPraxis Corporation Information
6.10.2 PharmaPraxis Description and Business Overview
6.10.3 PharmaPraxis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.10.4 PharmaPraxis Broluzumab Biosimilars Product Portfolio
6.10.5 PharmaPraxis Recent Developments/Updates
6.11 Samsung Bioepis
6.11.1 Samsung Bioepis Corporation Information
6.11.2 Samsung Bioepis Broluzumab Biosimilars Description and Business Overview
6.11.3 Samsung Bioepis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Samsung Bioepis Broluzumab Biosimilars Product Portfolio
6.11.5 Samsung Bioepis Recent Developments/Updates
6.12 Centus
6.12.1 Centus Corporation Information
6.12.2 Centus Broluzumab Biosimilars Description and Business Overview
6.12.3 Centus Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Centus Broluzumab Biosimilars Product Portfolio
6.12.5 Centus Recent Developments/Updates
6.13 Cadila Pharmaceuticals
6.13.1 Cadila Pharmaceuticals Corporation Information
6.13.2 Cadila Pharmaceuticals Broluzumab Biosimilars Description and Business Overview
6.13.3 Cadila Pharmaceuticals Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Cadila Pharmaceuticals Broluzumab Biosimilars Product Portfolio
6.13.5 Cadila Pharmaceuticals Recent Developments/Updates
6.14 Dr Reddy's
6.14.1 Dr Reddy's Corporation Information
6.14.2 Dr Reddy's Broluzumab Biosimilars Description and Business Overview
6.14.3 Dr Reddy's Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Dr Reddy's Broluzumab Biosimilars Product Portfolio
6.14.5 Dr Reddy's Recent Developments/Updates
6.15 Aurobindo Pharma
6.15.1 Aurobindo Pharma Corporation Information
6.15.2 Aurobindo Pharma Broluzumab Biosimilars Description and Business Overview
6.15.3 Aurobindo Pharma Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Aurobindo Pharma Broluzumab Biosimilars Product Portfolio
6.15.5 Aurobindo Pharma Recent Developments/Updates
6.16 Biocad
6.16.1 Biocad Corporation Information
6.16.2 Biocad Broluzumab Biosimilars Description and Business Overview
6.16.3 Biocad Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Biocad Broluzumab Biosimilars Product Portfolio
6.16.5 Biocad Recent Developments/Updates
6.17 MAbxience
6.17.1 MAbxience Corporation Information
6.17.2 MAbxience Broluzumab Biosimilars Description and Business Overview
6.17.3 MAbxience Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.17.4 MAbxience Broluzumab Biosimilars Product Portfolio
6.17.5 MAbxience Recent Developments/Updates
6.18 Hetero
6.18.1 Hetero Corporation Information
6.18.2 Hetero Broluzumab Biosimilars Description and Business Overview
6.18.3 Hetero Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Hetero Broluzumab Biosimilars Product Portfolio
6.18.5 Hetero Recent Developments/Updates
6.19 Biocon
6.19.1 Biocon Corporation Information
6.19.2 Biocon Broluzumab Biosimilars Description and Business Overview
6.19.3 Biocon Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Biocon Broluzumab Biosimilars Product Portfolio
6.19.5 Biocon Recent Developments/Updates
6.20 Kirin Biologics
6.20.1 Kirin Biologics Corporation Information
6.20.2 Kirin Biologics Broluzumab Biosimilars Description and Business Overview
6.20.3 Kirin Biologics Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Kirin Biologics Broluzumab Biosimilars Product Portfolio
6.20.5 Kirin Biologics Recent Developments/Updates
6.21 Mylan
6.21.1 Mylan Corporation Information
6.21.2 Mylan Broluzumab Biosimilars Description and Business Overview
6.21.3 Mylan Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Mylan Broluzumab Biosimilars Product Portfolio
6.21.5 Mylan Recent Developments/Updates
6.22 BeiGene
6.22.1 BeiGene Corporation Information
6.22.2 BeiGene Broluzumab Biosimilars Description and Business Overview
6.22.3 BeiGene Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.22.4 BeiGene Broluzumab Biosimilars Product Portfolio
6.22.5 BeiGene Recent Developments/Updates
6.23 Innovent
6.23.1 Innovent Corporation Information
6.23.2 Innovent Broluzumab Biosimilars Description and Business Overview
6.23.3 Innovent Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.23.4 Innovent Broluzumab Biosimilars Product Portfolio
6.23.5 Innovent Recent Developments/Updates
6.24 Qilu Pharmaceutical
6.24.1 Qilu Pharmaceutical Corporation Information
6.24.2 Qilu Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.24.3 Qilu Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.24.4 Qilu Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.24.5 Qilu Pharmaceutical Recent Developments/Updates
6.25 Hengrui Pharmaceuticals
6.25.1 Hengrui Pharmaceuticals Corporation Information
6.25.2 Hengrui Pharmaceuticals Broluzumab Biosimilars Description and Business Overview
6.25.3 Hengrui Pharmaceuticals Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.25.4 Hengrui Pharmaceuticals Broluzumab Biosimilars Product Portfolio
6.25.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.26 Hisun Pharmaceutical
6.26.1 Hisun Pharmaceutical Corporation Information
6.26.2 Hisun Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.26.3 Hisun Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.26.4 Hisun Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.26.5 Hisun Pharmaceutical Recent Developments/Updates
6.27 TOT BIOPHARM
6.27.1 TOT BIOPHARM Corporation Information
6.27.2 TOT BIOPHARM Broluzumab Biosimilars Description and Business Overview
6.27.3 TOT BIOPHARM Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.27.4 TOT BIOPHARM Broluzumab Biosimilars Product Portfolio
6.27.5 TOT BIOPHARM Recent Developments/Updates
6.28 Luye Pharmaceutical
6.28.1 Luye Pharmaceutical Corporation Information
6.28.2 Luye Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.28.3 Luye Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.28.4 Luye Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.28.5 Luye Pharmaceutical Recent Developments/Updates
6.29 Henlius
6.29.1 Henlius Corporation Information
6.29.2 Henlius Broluzumab Biosimilars Description and Business Overview
6.29.3 Henlius Broluzumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.29.4 Henlius Broluzumab Biosimilars Product Portfolio
6.29.5 Henlius Recent Developments/Updates
7 Broluzumab Biosimilars Manufacturing Cost Analysis
7.1 Broluzumab Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Broluzumab Biosimilars
7.4 Broluzumab Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Broluzumab Biosimilars Distributors List
8.3 Broluzumab Biosimilars Customers
9 Broluzumab Biosimilars Market Dynamics
9.1 Broluzumab Biosimilars Industry Trends
9.2 Broluzumab Biosimilars Market Drivers
9.3 Broluzumab Biosimilars Market Challenges
9.4 Broluzumab Biosimilars Market Restraints
10 Global Market Forecast
10.1 Broluzumab Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Broluzumab Biosimilars by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Broluzumab Biosimilars by Type (2023-2028)
10.2 Broluzumab Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Broluzumab Biosimilars by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Broluzumab Biosimilars by Application (2023-2028)
10.3 Broluzumab Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Broluzumab Biosimilars by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Broluzumab Biosimilars by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Global Broluzumab Biosimilars Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Broluzumab Biosimilars Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Broluzumab Biosimilars Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Broluzumab Biosimilars Market Competitive Situation by Manufacturers in 2021
Table 5. Global Broluzumab Biosimilars Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Broluzumab Biosimilars Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Broluzumab Biosimilars Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Broluzumab Biosimilars Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Broluzumab Biosimilars Average Price (K USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Broluzumab Biosimilars Manufacturing Sites and Area Served
Table 11. Manufacturers Broluzumab Biosimilars Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Broluzumab Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Broluzumab Biosimilars as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Broluzumab Biosimilars Sales by Region (2017-2022) & (K Units)
Table 16. Global Broluzumab Biosimilars Sales Market Share by Region (2017-2022)
Table 17. Global Broluzumab Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Broluzumab Biosimilars Revenue Market Share by Region (2017-2022)
Table 19. North America Broluzumab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 20. North America Broluzumab Biosimilars Sales Market Share by Country (2017-2022)
Table 21. North America Broluzumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Broluzumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 23. Europe Broluzumab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 24. Europe Broluzumab Biosimilars Sales Market Share by Country (2017-2022)
Table 25. Europe Broluzumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Broluzumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Broluzumab Biosimilars Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Broluzumab Biosimilars Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Broluzumab Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Broluzumab Biosimilars Revenue Market Share by Region (2017-2022)
Table 31. Latin America Broluzumab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Broluzumab Biosimilars Sales Market Share by Country (2017-2022)
Table 33. Latin America Broluzumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Broluzumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Broluzumab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Broluzumab Biosimilars Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Broluzumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Broluzumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 39. Global Broluzumab Biosimilars Sales by Type (2017-2022) & (K Units)
Table 40. Global Broluzumab Biosimilars Sales Market Share by Type (2017-2022)
Table 41. Global Broluzumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Broluzumab Biosimilars Revenue Share by Type (2017-2022)
Table 43. Global Broluzumab Biosimilars Price by Type (2017-2022) & (K USD/Unit)
Table 44. Global Broluzumab Biosimilars Sales (K Units) by Application (2017-2022)
Table 45. Global Broluzumab Biosimilars Sales Market Share by Application (2017-2022)
Table 46. Global Broluzumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Broluzumab Biosimilars Revenue Share by Application (2017-2022)
Table 48. Global Broluzumab Biosimilars Price by Application (2017-2022) & (K USD/Unit)
Table 49. Novartis Corporation Information
Table 50. Novartis Description and Business Overview
Table 51. Novartis Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 52. Novartis Broluzumab Biosimilars Product
Table 53. Novartis Recent Developments/Updates
Table 54. Genentech Corporation Information
Table 55. Genentech Description and Business Overview
Table 56. Genentech Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 57. Genentech Broluzumab Biosimilars Product
Table 58. Genentech Recent Developments/Updates
Table 59. Roche Corporation Information
Table 60. Roche Description and Business Overview
Table 61. Roche Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 62. Roche Broluzumab Biosimilars Product
Table 63. Roche Recent Developments/Updates
Table 64. Pfizer Corporation Information
Table 65. Pfizer Description and Business Overview
Table 66. Pfizer Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 67. Pfizer Broluzumab Biosimilars Product
Table 68. Pfizer Recent Developments/Updates
Table 69. Sartorius Corporation Information
Table 70. Sartorius Description and Business Overview
Table 71. Sartorius Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 72. Sartorius Broluzumab Biosimilars Product
Table 73. Sartorius Recent Developments/Updates
Table 74. Eli Lilly Corporation Information
Table 75. Eli Lilly Description and Business Overview
Table 76. Eli Lilly Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 77. Eli Lilly Broluzumab Biosimilars Product
Table 78. Eli Lilly Recent Developments/Updates
Table 79. Bayer Corporation Information
Table 80. Bayer Description and Business Overview
Table 81. Bayer Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 82. Bayer Broluzumab Biosimilars Product
Table 83. Bayer Recent Developments/Updates
Table 84. Amgen Corporation Information
Table 85. Amgen Description and Business Overview
Table 86. Amgen Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 87. Amgen Broluzumab Biosimilars Product
Table 88. Amgen Recent Developments/Updates
Table 89. PlantForm Corporation Information
Table 90. PlantForm Description and Business Overview
Table 91. PlantForm Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 92. PlantForm Broluzumab Biosimilars Product
Table 93. PlantForm Recent Developments/Updates
Table 94. PharmaPraxis Corporation Information
Table 95. PharmaPraxis Description and Business Overview
Table 96. PharmaPraxis Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 97. PharmaPraxis Broluzumab Biosimilars Product
Table 98. PharmaPraxis Recent Developments/Updates
Table 99. Samsung Bioepis Corporation Information
Table 100. Samsung Bioepis Description and Business Overview
Table 101. Samsung Bioepis Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 102. Samsung Bioepis Broluzumab Biosimilars Product
Table 103. Samsung Bioepis Recent Developments/Updates
Table 104. Centus Corporation Information
Table 105. Centus Description and Business Overview
Table 106. Centus Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 107. Centus Broluzumab Biosimilars Product
Table 108. Centus Recent Developments/Updates
Table 109. Cadila Pharmaceuticals Corporation Information
Table 110. Cadila Pharmaceuticals Description and Business Overview
Table 111. Cadila Pharmaceuticals Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 112. Cadila Pharmaceuticals Broluzumab Biosimilars Product
Table 113. Cadila Pharmaceuticals Recent Developments/Updates
Table 114. Dr Reddy's Corporation Information
Table 115. Dr Reddy's Description and Business Overview
Table 116. Dr Reddy's Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 117. Dr Reddy's Broluzumab Biosimilars Product
Table 118. Dr Reddy's Recent Developments/Updates
Table 119. Aurobindo Pharma Corporation Information
Table 120. Aurobindo Pharma Description and Business Overview
Table 121. Aurobindo Pharma Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 122. Aurobindo Pharma Broluzumab Biosimilars Product
Table 123. Aurobindo Pharma Recent Developments/Updates
Table 124. Biocad Corporation Information
Table 125. Biocad Description and Business Overview
Table 126. Biocad Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 127. Biocad Broluzumab Biosimilars Product
Table 128. Biocad Recent Developments/Updates
Table 129. MAbxience Corporation Information
Table 130. MAbxience Description and Business Overview
Table 131. MAbxience Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 132. MAbxience Broluzumab Biosimilars Product
Table 133. MAbxience Recent Developments/Updates
Table 134. Hetero Corporation Information
Table 135. Hetero Description and Business Overview
Table 136. Hetero Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 137. Hetero Broluzumab Biosimilars Product
Table 138. Hetero Recent Developments/Updates
Table 139. Biocon Corporation Information
Table 140. Biocon Description and Business Overview
Table 141. Biocon Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 142. Biocon Broluzumab Biosimilars Product
Table 143. Biocon Recent Developments/Updates
Table 144. Kirin Biologics Corporation Information
Table 145. Kirin Biologics Description and Business Overview
Table 146. Kirin Biologics Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 147. Kirin Biologics Broluzumab Biosimilars Product
Table 148. Kirin Biologics Recent Developments/Updates
Table 149. Mylan Corporation Information
Table 150. Mylan Description and Business Overview
Table 151. Mylan Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 152. Mylan Broluzumab Biosimilars Product
Table 153. Mylan Recent Developments/Updates
Table 154. BeiGene Corporation Information
Table 155. BeiGene Description and Business Overview
Table 156. BeiGene Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 157. BeiGene Broluzumab Biosimilars Product
Table 158. BeiGene Recent Developments/Updates
Table 159. Innovent Corporation Information
Table 160. Innovent Description and Business Overview
Table 161. Innovent Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 162. Innovent Broluzumab Biosimilars Product
Table 163. Innovent Recent Developments/Updates
Table 164. Qilu Pharmaceutical Corporation Information
Table 165. Qilu Pharmaceutical Description and Business Overview
Table 166. Qilu Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 167. Qilu Pharmaceutical Broluzumab Biosimilars Product
Table 168. Qilu Pharmaceutical Recent Developments/Updates
Table 169. Hengrui Pharmaceuticals Corporation Information
Table 170. Hengrui Pharmaceuticals Description and Business Overview
Table 171. Hengrui Pharmaceuticals Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 172. Hengrui Pharmaceuticals Broluzumab Biosimilars Product
Table 173. Hengrui Pharmaceuticals Recent Developments/Updates
Table 174. Hisun Pharmaceutical Corporation Information
Table 175. Hisun Pharmaceutical Description and Business Overview
Table 176. Hisun Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 177. Hisun Pharmaceutical Broluzumab Biosimilars Product
Table 178. Hisun Pharmaceutical Recent Developments/Updates
Table 179. TOT BIOPHARM Corporation Information
Table 180. TOT BIOPHARM Description and Business Overview
Table 181. TOT BIOPHARM Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 182. TOT BIOPHARM Broluzumab Biosimilars Product
Table 183. TOT BIOPHARM Recent Developments/Updates
Table 184. Luye Pharmaceutical Corporation Information
Table 185. Luye Pharmaceutical Description and Business Overview
Table 186. Luye Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 187. Luye Pharmaceutical Broluzumab Biosimilars Product
Table 188. Luye Pharmaceutical Recent Developments/Updates
Table 189. Henlius Corporation Information
Table 190. Henlius Description and Business Overview
Table 191. Henlius Broluzumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 192. Henlius Broluzumab Biosimilars Product
Table 193. Henlius Recent Developments/Updates
Table 194. Production Base and Market Concentration Rate of Raw Material
Table 195. Key Suppliers of Raw Materials
Table 196. Broluzumab Biosimilars Distributors List
Table 197. Broluzumab Biosimilars Customers List
Table 198. Broluzumab Biosimilars Market Trends
Table 199. Broluzumab Biosimilars Market Drivers
Table 200. Broluzumab Biosimilars Market Challenges
Table 201. Broluzumab Biosimilars Market Restraints
Table 202. Global Broluzumab Biosimilars Sales Forecast by Type (2023-2028) & (K Units)
Table 203. Global Broluzumab Biosimilars Sales Market Share Forecast by Type (2023-2028)
Table 204. Global Broluzumab Biosimilars Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 205. Global Broluzumab Biosimilars Revenue Market Share Forecast by Type (2023-2028)
Table 206. Global Broluzumab Biosimilars Sales Forecast by Application (2023-2028) & (K Units)
Table 207. Global Broluzumab Biosimilars Sales Market Share Forecast by Application (2023-2028)
Table 208. Global Broluzumab Biosimilars Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 209. Global Broluzumab Biosimilars Revenue Market Share Forecast by Application (2023-2028)
Table 210. Global Broluzumab Biosimilars Sales Forecast by Region (2023-2028) & (K Units)
Table 211. Global Broluzumab Biosimilars Sales Market Share Forecast by Region (2023-2028)
Table 212. Global Broluzumab Biosimilars Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 213. Global Broluzumab Biosimilars Revenue Market Share Forecast by Region (2023-2028)
Table 214. Research Programs/Design for This Report
Table 215. Key Data Information from Secondary Sources
Table 216. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Broluzumab Biosimilars
Figure 2. Global Broluzumab Biosimilars Market Share by Type in 2021 & 2028
Figure 3. Beovu Product Picture
Figure 4. Vsiqq Product Picture
Figure 5. Others Product Picture
Figure 6. Global Broluzumab Biosimilars Market Share by Application in 2021 & 2028
Figure 7. ARMD
Figure 8. Kaposi Sarcoma
Figure 9. Glioblastoma
Figure 10. Global Broluzumab Biosimilars Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Broluzumab Biosimilars Market Size (2017-2028) & (US$ Million)
Figure 12. Global Broluzumab Biosimilars Sales (2017-2028) & (K Units)
Figure 13. Broluzumab Biosimilars Sales Share by Manufacturers in 2021
Figure 14. Global Broluzumab Biosimilars Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Broluzumab Biosimilars Players: Market Share by Revenue in 2021
Figure 16. Broluzumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Broluzumab Biosimilars Sales Market Share by Region (2017-2022)
Figure 18. Global Broluzumab Biosimilars Sales Market Share by Region in 2021
Figure 19. Global Broluzumab Biosimilars Revenue Market Share by Region (2017-2022)
Figure 20. Global Broluzumab Biosimilars Revenue Market Share by Region in 2021
Figure 21. United States Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Canada Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Germany Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. France Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. U.K. Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Italy Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Russia Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. China Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Japan Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. South Korea Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. India Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Australia Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. China Taiwan Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Indonesia Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Thailand Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Malaysia Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Mexico Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Brazil Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Argentina Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Turkey Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Saudi Arabia Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. UAE Broluzumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Sales Market Share of Broluzumab Biosimilars by Type (2017-2022)
Figure 44. Manufacturing Cost Structure of Broluzumab Biosimilars
Figure 45. Manufacturing Process Analysis of Broluzumab Biosimilars
Figure 46. Broluzumab Biosimilars Industrial Chain Analysis
Figure 47. Channels of Distribution
Figure 48. Distributors Profiles
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
